Immunotherapy Innovation Immunocore is a pioneer in developing novel TCR bispecific immunotherapies, such as ImmTAX, designed to treat cancer, autoimmune, and infectious diseases. These innovative therapies present sales opportunities for partnerships and collaborations in advancing cutting-edge treatments.
Strategic Partnership Immunocore's recent partnership with Genedata signifies a focus on scaling up the discovery of novel TCR therapeutics. This partnership opens doors for potential sales engagements in providing technological solutions and support to enhance the company's therapeutic development processes.
Public Offering Impact Immunocore's successful initial public offering highlights its financial growth and market presence. This key milestone could lead to sales opportunities in offering financial services, strategic consultancy, and investment opportunities to support the company's expansion and development initiatives.
Leadership Transition The upcoming departure of Immunocore's CFO and Head of Strategy presents a potential sales opportunity for recruitment firms or leadership development consultants to offer their services in sourcing top talent for key executive positions within the company.
Pipeline Expansion Immunocore's focus on developing a pipeline of treatments for various diseases through its proprietary TCR technology signifies growth and diversification. Sales opportunities exist in providing specialized services or products that support the expansion and clinical trial processes of the company's treatment pipeline.
565
$100M$1B
296$50M$100M
101$10M$50M
106$10M$50M
201$50M$100MImmunocore uses 8 technology products and services including Linkedin Insight Tag, Skillsoft, Microsoft Word, and more. Explore Immunocore's tech stack below.
| Immunocore Email Formats | Percentage |
| First.Last@immunocore.com | 94% |
| F.Last@immunocore.com | 3% |
| First@immunocore.com | 2% |
| First.Middle@immunocore.com | 1% |
Biotechnology ResearchOxfordshire, United Kingdom501-1000 Employees
Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr
Company Overview
Funding & FinancialsImmunocore has raised a total of $350M of funding over 8 rounds. Their latest funding round was raised on Jan 30, 2024 in the amount of $350M.
Immunocore's revenue is in the range of $50M$100M
Funding & FinancialsImmunocore has raised a total of $350M of funding over 8 rounds. Their latest funding round was raised on Jan 30, 2024 in the amount of $350M.
Immunocore's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com